公开(公告)号：US20170305903A1

公开(公告)日：2017-10-26

申请号：US15581642

申请日：2017-04-28

Applicant: Novartis AG

Inventor： Dirk BEHNKE ,  David CARCACHE ,  Peter ERTL ,  Manuel KOLLER ,  David ORAIN

IPC: C07D471/04 ,  C07D519/00 ,  A61K31/551

Abstract: The invention relates to compound of the formula I or a salt thereof, wherein the substituents are as defined in the specification; to its preparation, to its use as medicament and to medicaments comprising it.

公开(公告)号：US20130296332A1

公开(公告)日：2013-11-07

申请号：US13932173

申请日：2013-07-01

Applicant: NOVARTIS AG

Inventor： Hans ALLGEIER ,  Yves AUBERSON ,  David CARCACHE ,  Philipp FLOERSHEIM ,  Christel GUIBOURDENCHE ,  Wolfgang FROESTL ,  Jörg KALLEN ,  Manuel KOLLER ,  Henri MATTES ,  Joachim NOZULAK ,  David ORAIN ,  Johanne RENAUD

IPC: C07D239/96 ,  C07C207/00 ,  C07C229/56 ,  C07D413/04 ,  C07D405/04 ,  C07D403/04 ,  C07C271/58

CPC classification number: C07D239/96 ,  C07C207/00 ,  C07C229/56 ,  C07C229/64 ,  C07C229/66 ,  C07C255/18 ,  C07C265/12 ,  C07C271/58 ,  C07D207/337 ,  C07D231/12 ,  C07D237/08 ,  C07D239/26 ,  C07D241/12 ,  C07D249/06 ,  C07D263/32 ,  C07D307/16 ,  C07D307/54 ,  C07D309/12 ,  C07D401/04 ,  C07D403/04 ,  C07D405/04 ,  C07D413/04

Abstract: The present invention relates to 1H-Quinazoline-2,4-diones of formula (I) wherein R1 and R2 are as defined in the specification, their preparation, their use as pharmaceuticals, and pharmaceutical compositions containing them. Further, intermediates for the manufacture of compounds of formula (I) are and combinations comprising compounds of formula (I) are disclosed.

Abstract translation: 本发明涉及式（I）的1H-喹唑啉-2,4-二酮，其中R 1和R 2如说明书中所定义，其制备，作为药物的用途，以及含有它们的药物组合物。 此外，公开了用于制备式（I）化合物的中间体和包含式（I）化合物的组合。

公开(公告)号：US20140256940A1

公开(公告)日：2014-09-11

申请号：US14285942

申请日：2014-05-23

Applicant: NOVARTIS AG

Inventor： Mathias FREDERIKSEN ,  Dominik FEUERBACH ,  Konstanze HURTH ,  Manuel KOLLER ,  Bernard Lucien ROY

IPC: C07D471/08

CPC classification number: C07D471/08 ,  A61K31/429

Abstract: The present invention related to compounds of formula (I) wherein n represents 0, 1, 2, 3, 4 or 5, represents independent from each other hydroxyl, cyano, nitro, halogen, alkyl, alkoxy alkylcarbonyl, alkoxycarbonyl, alkylamine, dialkylamine, alkylcarbonylamine, alkylcarbamate, Y represents one of the following groups: (Ia) in free base or acid addition salt form, to processes for their production, to pharmaceutical compositions comprising them and their use in the manufacture of a medicament for the treatment and/or delay of progression of psychotic and neurodegenerative disorders.

Abstract translation: 本发明涉及式（I）化合物，其中n代表0,1,2,3,4或5相互独立地表示羟基，氰基，硝基，卤素，烷基，烷氧基烷基羰基，烷氧基羰基，烷基胺，二烷基胺， 烷基羰基胺，烷基氨基甲酸酯，Y代表以下基团之一：游离碱或酸加成盐形式的（Ia），其制备方法，包含它们的药物组合物及其在制备用于治疗和/或 延迟精神病和神经退行性疾病的进展。